ORAMED PHARMACEUTICALS INC. (ORMP) Stock Profile — Insider Trades & Financials

Smart-Money SignalNeutral · 52/100— Insiders are net sellers over 90 days (-$226K, 2 sales vs 0 buys)

Revenue$0

Net Income$78.2M

EPS$2.76

Market Cap$172.3M

Price Performance

Historical data including institutional events

Company Profile

Nadav Kidron

CEO & Executive Director

Oramed Pharmaceuticals Inc., is a publicly traded company engaged in the development of oral drug delivery systems – most notably an oral insulin capsule for treating type 2 diabetes. The company was founded in 2006 and is headquartered in Jerusalem. Its shares are listed on the NASDAQ Capital Market and the Tel Aviv Stock Exchange.

Founded: 2002
Employees: 4
Headquarters: NEW YORK, NY, United States
Website: www.oramed.com

Peer ComparisonRevenue ($B)

▾

Loading company sections...

Smart-Money SignalNeutral · 52/100— Insiders are net sellers over 90 days (-$226K, 2 sales vs 0 buys)

Revenue$0

Net Income$78.2M

EPS$2.76

Market Cap$172.3M

Price Performance

Historical data including institutional events

Company Profile

Nadav Kidron

CEO & Executive Director

Founded: 2002
Employees: 4
Headquarters: NEW YORK, NY, United States
Website: www.oramed.com

Peer ComparisonRevenue ($B)

▾

Smart-Money Signal

90-DAY POSTURE

52/ 100

NEUTRAL

Insiders are net sellers over 90 days (-$226K, 2 sales vs 0 buys). Smart-money posture is balanced.

Insider flow · 90d-$226K

Congress flow · 90dno activity

10b5-1 share100% planned

Cluster selling2 officers

Price vs 52w78% of high

Cross-Section Event Timeline

INSIDERS · CONGRESS · EARNINGS

INSIDER GRANT / AWARDAvraham Gabay (Chief Financial Officer) GRANT / AWARD ORMPSep 24, 2026

INSIDER GRANT / AWARDMiriam Kidron (Chief Scientific Officer) GRANT / AWARD ORMPSep 24, 2026

INSIDERMiriam Kidron (Chief Scientific Officer) DISPOSITION TO ISSUER ORMPSep 24, 2026

INSIDERJoshua Hexter (COO & CBO) DISPOSITION TO ISSUER ORMPSep 24, 2026

INSIDER GRANT / AWARDJoshua Hexter (COO & CBO) GRANT / AWARD ORMPSep 24, 2026

INSIDER GRANT / AWARDNadav Kidron (President and CEO) GRANT / AWARD ORMPSep 24, 2026

INSIDER SELLJoshua Hexter (COO & CBO) SELL ORMPOct 1, 2026

INSIDER SELLAvraham Gabay (Chief Financial Officer) SELL ORMPOct 1, 2026

⚡

Core Efficiency

ROE?

24.62%

ROA?

21.14%

📊

Profitability Ratios

Current Ratio?

4.98

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Nov 23, 2026 (in 40 days)

Quarterly Report (10-Q) — Based on filing pattern

Nov 23, 2026

Predicted10-Q

Aug 10, 2026

10-QQ2 202641d after period end

May 19, 2026

10-QQ1 202649d after period end

Mar 26, 2026

10-KQ4 202585d after period end

Mar 26, 2026

10-KFY 202585d after period end

Nov 13, 2025

10-QQ3 202544d after period end

Aug 14, 2025

10-QQ2 202545d after period end

May 15, 2025

10-QQ1 202545d after period end

Mar 27, 2025

10-KQ4 202486d after period end

Data Freshness

Financial Data

2mo ago

Latest filing: 2026-08-10

SEC Metadata

2mo ago

Latest filing: 2026-08-10

Loading company sections...

ORAMED PHARMACEUTICALS INC.

Price Performance

Company Profile

ORAMED PHARMACEUTICALS INC.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness

Recent Insider Trades

Recent Congress Trades

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness

Recent Insider Trades

Recent Congress Trades

ORAMED PHARMACEUTICALS INC.

Price Performance

Company Profile

The morning brief, before the bell.

ORAMED PHARMACEUTICALS INC.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness

Recent Insider Trades

Recent Congress Trades

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness

Recent Insider Trades

Recent Congress Trades